Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
Total Valuation
Marker Therapeutics has a market cap or net worth of $22.01M. The enterprise value is -$16.07T.
Market Cap$22.01M
Enterprise Value-$16.07T
Share Statistics
Marker Therapeutics has 16,673,126 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,673,126
Owned by Insiders18.09%
Owned by Institutions15.56%
Financial Efficiency
Marker Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is >-0.01%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)>-0.01%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee709.33K
Profits Per Employee-2.43T
Employee Count5
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Marker Therapeutics is ―. Marker Therapeutics’s PEG ratio is 0.06.
PE Ratio―
PS Ratio6.43
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio0.06
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 3.55M and earned -12.16M in profits. Earnings per share was -0.79.
Revenue3.55M
Gross Profit0.00
Operating Income-12.44M
Pretax Income-12.18M
Net Income-12.16M
EBITDA-12.44M
Earnings Per Share (EPS)-0.79
Cash Flow
In the last 12 months, operating cash flow was -12.01T and capital expenditures -7.00, giving a free cash flow of -12.01T billion.
Operating Cash Flow-12.01T
Free Cash Flow-12.01T
Free Cash Flow per Share-720.57K
Dividends & Yields
Marker Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.62
52-Week Price Change30.69%
50-Day Moving Average1.49
200-Day Moving Average1.32
Relative Strength Index (RSI)45.40
Average Volume (3m)125.54K
Important Dates
Marker Therapeutics upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateMar 18, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Marker Therapeutics as a current ratio of 8.39, with Debt / Equity ratio of 0.00%
Current Ratio8.39
Quick Ratio8.39
Debt to Market Cap0.00
Net Debt to EBITDA1.29M
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Marker Therapeutics has paid -15.16K in taxes.
Income Tax-15.16K
Effective Tax Rate<0.01
Enterprise Valuation
Marker Therapeutics EV to EBITDA ratio is 1.29M, with an EV/FCF ratio of 1.34.
EV to Sales-4.53M
EV to EBITDA1.29M
EV to Free Cash Flow1.34
EV to Operating Cash Flow1.34
Balance Sheet
Marker Therapeutics has $16.07T in cash and marketable securities with $0.00 in debt, giving a net cash position of $16.07T billion.
Cash & Marketable Securities$16.07T
Total Debt$0.00
Net Cash$16.07T
Net Cash Per Share$963.71K
Tangible Book Value Per Share$1.10M
Margins
Gross margin is -137.29%, with operating margin of -350.68%, and net profit margin of -342.96%.
Gross Margin-137.29%
Operating Margin-350.68%
Pretax Margin-343.39%
Net Profit Margin-342.96%
EBITDA Margin-350.68%
EBIT Margin-350.68%
Analyst Forecast
The average price target for Marker Therapeutics is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.00
Price Target Upside581.82% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-12.99%
EPS Growth Forecast-13.67%